The DOI matches its Crossref record; 134 of the 136 references it cites were found in a registry or an index; 22 of the 198 sources its claims cite were checked for support.
Recent Advancements in Pathogenesis, Diagnostics and Treatment of Alzheimer’s Disease
Open accessAbstract
BACKGROUND: The only conclusive way to diagnose Alzheimer's is to carry out brain autopsy of the patient's brain tissue and ascertain whether the subject had Alzheimer's or any other form of dementia. However, due to the non-feasibility of such methods, to diagnose and conclude the conditions, medical practitioners use tests that examine a patient's mental ability. OBJECTIVE: Accurate diagnosis at an early stage is the need of the hour for initiation of therapy. The cause for most Alzheimer's cases still remains unknown except where genetic distinctions have been observed. Thus, a standard drug regimen ensues in every Alzheimer's patient, irrespective of the cause, which may not always be beneficial in halting or reversing the disease progression. To provide a better life to such patients by suppressing existing symptoms, early diagnosis, curative therapy, site-specific delivery of drugs, and application of hyphenated methods like artificial intelligence need to be brought into the main field of Alzheimer's therapeutics. METHODS: In this review, we have compiled existing hypotheses to explain the cause of the disease, and highlighted gene therapy, immunotherapy, peptidomimetics, metal chelators, probiotics and quantum dots as advancements in the existing strategies to manage Alzheimer's. CONCLUSION: Biomarkers, brain-imaging, and theranostics, along with artificial intelligence, are understood to be the future of the management of Alzheimer's.
Overview
CoChat Summary
TL;DR
This narrative review summarizes proposed mechanisms of Alzheimer’s disease (AD), current diagnostic approaches, and emerging therapeutic strategies including gene therapy, immunotherapy, peptidomimetics, metal chelators, probiotics, theranostics/quantum dots, and artificial intelligence. It argues that early diagnosis and multimodal, mechanism-targeted approaches are needed because existing treatments only relieve symptoms and no available drug halts or reverses disease progression.
Key findings
- AD pathogenesis is described through multiple hypotheses: Aβ plaque formation, tau hyperphosphorylation and neurofibrillary tangles, synaptic dysfunction and neurotransmitter imbalance, neuroinflammation, infectious disease, gut microbiome disruption, genetic mutations, oxidative stress, and autophagy dysfunction. The review notes that amyloid-targeting drugs have shown no effect in reversing or halting cognitive decline, suggesting either the hypothesis is incorrect or the brain becomes refractory after a certain time.
- For diagnosis, the paper reports that specialized PET scanning exhibits 100% specificity and 96% sensitivity in AD and milder conditions, while CSF analysis for p-tau, Aβ42, and total tau has 85–90% accuracy. It also states that pathological changes are initiated two decades before symptoms appear, and that P-tau181 can serve as a confirmatory and prognostic biomarker.
- Currently approved drugs target cholinergic or glutamatergic neurotransmission: donepezil, rivastigmine, and galantamine are acetylcholinesterase inhibitors effective in mild to moderate AD; memantine, approved by the FDA in 2003, is an NMDA receptor antagonist for moderate to severe AD. These drugs only relieve symptoms, and no drug is available with a curative effect.
- Emerging strategies include gene therapy, immunotherapy, peptidomimetics, metal chelators, probiotics/prebiotics/exercise, theranostics with quantum dots, and AI-based diagnosis. Examples include deep learning with 18F-FDG PET achieving 82% specificity and 100% sensitivity at an average of 75.8 months ahead of final diagnosis, and voice/speech machine-learning classifiers reporting accuracies from 74% to 94.71%.
Methods
- Design: narrative review compiling existing hypotheses and highlighting gene therapy, immunotherapy, peptidomimetics, metal chelators, probiotics, and quantum dots as advancements in AD management.
- Data/sample: no primary data collection; the paper synthesizes prior literature, including human trials, animal models, and biomarker studies.
- Main analysis: qualitative synthesis of mechanisms, diagnostics, current FDA-approved medicines, and future therapeutic/diagnostic approaches, including artificial intelligence.
Limitations
- Stated in the paper: various hypotheses are unable to explain the complete picture of AD pathogenesis; the cause in many cases remains untraceable; no treatment options can halt or reverse disease progression; gene therapy and quantum dots are recent additions but are yet to be clinically approved; most immunotherapeutics are in Phase 3 clinical trials; peptidomimetics, speech as an indicator, and metal ion chelators are still under investigation and not widely used.
- Evident from the text: this is a narrative review without a described systematic search strategy, formal inclusion/exclusion criteria, or meta-analysis; it relies on cited studies that include animal models, small cohorts, and preliminary human data, and it does not perform a formal risk-of-bias or quality assessment.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
20 Valid · 2 Not valid · 159 Not checked · 11 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“Alteration in the activity of any of these gut microbes along with increase nitrate intake, can lead to overproduction of NO, which can cause axonal degeneration, neuro inflammation and neurodegenerative disorders [24].”
§ Recent Advancements in Pathogenesis, Diagnostics and Treatment of Alzheimer’s Disease > Introduction > Mechanisms of Alzheimer’s Disease
What the sources say
- Supportedcites [24] Luca M.; Di Mauro M.; Di Mauro M.; Luca A.; Gut microbiota in alzheimer’s disease, depression, and type 2 diabetes mellitus: the role of oxidative stress. Oxid Med Cell Longev 2019,2019 source
Section 1.3 (Microbiota, Inflammation, and Oxidative Stress) of our copy states the full chain the claim attributes: a high nitrate intake increases nitrite concentration and NO, gut lactobacilli and bifidobacteria convert nitrate and nitrite into NO (streptomycetes and bacilli make NO via NOS), and 'excessive NO production is noxious, being associated with neuroinflammation, cellular damage, axonal degeneration, and neurodegenerative disorders'. Section 3.1 adds that an altered microbiota can stimulate NO synthesis, covering the 'alteration in the activity of gut microbes' element. Luca et al. is a review that reports these points (crediting the microbial NO chemistry to their ref [23], Oleskin & Shenderov, and the NO-toxicity consequences to their ref [10]), so it supports the paraphrase as a secondary source rather than as the original study. (LLM, conf=0.82)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Metal ions specifically zinc and copper may bind to the Aβ plaque and produce ROS.”
§ Recent Advancements in Pathogenesis, Diagnostics and Treatment of Alzheimer’s Disease > Introduction > Mechanisms of Alzheimer’s Disease
What the sources say
- Partly supportedcites [24] Luca M.; Di Mauro M.; Di Mauro M.; Luca A.; Gut microbiota in alzheimer’s disease, depression, and type 2 diabetes mellitus: the role of oxidative stress. Oxid Med Cell Longev 2019,2019 sourceExperimental — accuracy not yet measured
Section 2.1 identifies copper and zinc accumulated in neuritic plaques as sources of ROS production. It does not specifically say that those ions bind to Aβ, so the proposed binding mechanism is not established by this paper. (LLM, conf=0.84)
- Partly supportedcites [29] Moreira P.I.; Carvalho C.; Zhu X.; Smith M.A.; Perry G.; Mitochondrial dysfunction is a trigger of Alzheimer’s disease pathophysiology. Biochim Biophys Acta 2010,1802(1),2-10 sourceExperimental — accuracy not yet measured
Section 3 reports that Aβ exposure stimulates hydrogen peroxide generation, supporting the broader link between Aβ and reactive oxygen species. Sections 2 and 3 do not say that zinc or copper binds Aβ plaques or that such binding produces ROS; the paper instead discusses mitochondrial ROS generation and, separately, reactions involving reduced transition metals. (LLM, conf=0.82)
- Partly supportedcites [30] Cheignon C.; Tomas M.; Bonnefont-Rousselot D.; Faller P.; Hureau C.; Collin F.; Oxidative stress and the amyloid beta peptide in Alzheimer’s disease. Redox Biol 2018,14,450-464 sourceExperimental — accuracy not yet measured
Section 2.2 says copper and zinc can bind Aβ, but identifies copper-containing aggregates—not zinc-containing ones—as capable of producing ROS. Section 4.2 likewise discusses ROS production by Cu–Aβ complexes. The claim is therefore supported for copper binding and ROS production, but not for zinc producing ROS. (LLM, conf=0.88)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“An increase in tau acetylation was linked to the loss of KIBRA in AD patients with dementia.”
§ Recent Advancements in Pathogenesis, Diagnostics and Treatment of Alzheimer’s Disease > Newer strategies in early detection of Alzheimer’s disease > Kidney/Brain (KIBRA) Protein, a Memory-Associated Protein
What the sources say
- Supportedcites [76] Tracy T.E.; Sohn P.D.; Minami S.S.; Wang C.; Min S.W.; Li Y.; Zhou Y.; Le D.; Lo I.; Ponnusamy R.; Cong X.; Schilling B.; Ellerby L.M.; Huganir R.L.; Gan L.; Acetylated tau obstructs KIBRA-mediated signaling in synaptic plasticity and promotes tauopathy related memory loss. Neuron 2016,90(2),245-260 source
The Results section reports that elevated tau acetylation at K274 or K281 correlates strongly with reduced KIBRA protein in AD, and that KIBRA levels are significantly lower in severely demented cases. The Discussion likewise states that dementia in AD is associated with elevated acetylation at those sites and negatively correlated KIBRA levels. (LLM, conf=0.95)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“The strongest and most reliable genetic association involves the epsilon 4 (ε4) allele at the ApoE locus for increased risk of late-onset AD [68, 69].”
§ Recent Advancements in Pathogenesis, Diagnostics and Treatment of Alzheimer’s Disease > Newer strategies in early detection of Alzheimer’s disease > Genetic Markers
What the sources say
- Supportedcites [68] Harold D.; Abraham R.; Hollingworth P.; Sims R.; Gerrish A.; Hamshere M.L.; Pahwa J.S.; Moskvina V.; Dowzell K.; Williams A.; Jones N.; Thomas C.; Stretton A.; Morgan A.R.; Lovestone S.; Powell J.; Proitsi P.; Lupton M.K.; Brayne C.; Rubinsztein D.C.; Gill M.; Lawlor B.; Lynch A.; Morgan K.; Brown K.S.; Passmore P.A.; Craig D.; McGuinness B.; Todd S.; Holmes C.; Mann D.; Smith A.D.; Love S.; Kehoe P.G.; Hardy J.; Mead S.; Fox N.; Rossor M.; Collinge J.; Maier W.; Jessen F.; Schürmann B.; Heun R.; van den Bussche H.; Heuser I.; Kornhuber J.; Wiltfang J.; Dichgans M.; Frölich L.; Hampel H.; Hüll source
The paper’s introductory discussion (page unavailable) calls APOE the only unequivocally established susceptibility gene for the common form of AD and says its association is stronger than those found for other genes. The Secondary Analyses section identifies the APOE ε4 allele and reports substantially more ε4-positive AD cases than controls, supporting the claim that it is associated with increased risk. (LLM, conf=0.90)
- Not checked yetcites [69] Poirier J.; Davignon J.; Bouthillier D.; Kogan S.; Bertrand P.; Gauthier S.; Apolipoprotein E polymorphism and Alzheimer’s disease. Lancet 1993,342(8873),697-699 source
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In another study, an immuno‐infrared‐sensor was used for the extraction of the total Aβ fraction from plasma samples, wherein the biomarker amide I band were significantly lower for AD individuals.”
§ Recent Advancements in Pathogenesis, Diagnostics and Treatment of Alzheimer’s Disease > Newer strategies in early detection of Alzheimer’s disease > Blood and Urine Biomarkers of AD
What the sources say
- Supportedcites [60] Nabers A.; Perna L.; Lange J.; Mons U.; Schartner J.; Güldenhaupt J.; Saum K.U.; Janelidze S.; Holleczek B.; Rujescu D.; Hansson O.; Gerwert K.; Brenner H.; Amyloid blood biomarker detects Alzheimer’s disease. EMBO Mol Med 2018,10(5) source
The ESTHER Results state that the immuno-infrared sensor extracted the total Aβ fraction from plasma and that the amide I biomarker band was significantly lower in AD cases than controls (P < 0.001). The BioFINDER Results also report a significantly lower band in prodromal AD cases. The measured decrease is in the band's position or frequency, not the amount of Aβ. (LLM, conf=0.95)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
89 more claims · 5 with their cited sources checked
Create a free account to see all 192 claims and to verify the 176 references still open.
- It may state two separate claims as one. 90
- Probably not a substantial claim. 12
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Chronic neuroinflammation—driven by activated microglia and oxidative stress from protein aggregates—creates a vicious cycle that worsens proteopathy and impairs autophagy [7].”
From Theranostic Nanoplatforms for Alzheimer's Disease: A Critical Analysis of Conceptual Contradictions (2026) · cites this paper as [7]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“The dementia group included 314 patients (249 diagnosed with probable AD, 21 suffering from possible AD, 5 with VD (Vascular dementia), 3 with problems related to memory, 43 with Mild cognitive impairment and 4 with undiscovered form of dementia)”
§ Recent Advancements in Pathogenesis, Diagnostics and Treatment of Alzheimer’s Disease > Current strategies in the treatment of Alzheimer’s disease > Voice as a Biomarker Using Artificial Intelligence
Reported 314 · recomputed 325
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Recent Advancements in Pathogenesis, Diagnostics and Treatment of Alzheimer’s Disease > Introduction > Diagnostics of Alzheimer’s Disease
“PET scanning and CSF analysis revealed that the pathological changes are initiated two decades before the appearance of symptoms”
§ Recent Advancements in Pathogenesis, Diagnostics and Treatment of Alzheimer’s Disease > Current strategies in the treatment of Alzheimer’s disease
“the emergence of AD-related pathologic changes begins quite early, almost a decade before the person shows the symptoms.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Recent Advancements in Pathogenesis, Diagnostics and Treatment of Alzheimer’s Disease > Introduction
“were the nine countries in descending order of incidence of people suffering from dementia in 2010”
§ Recent Advancements in Pathogenesis, Diagnostics and Treatment of Alzheimer’s Disease > Introduction
“China, USA, India, Japan, Germany, Russia, France and Brazil”
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152 · cited 1×
“This criterion set is the prevailing standard for the MCI syndrome in current times, and is reflected in the NIAAA work group guidelines for the diagnosis of MCI due to AD [87].”
BackgroundMild Cognitive Impairment: Clinical Characterization and Outcome
Petersen, R. C., Smith, G. E., Waring, S. C., Ivnik, R. J., Tangalos, E. G., & Kokmen, E. (1999) · Archives of Neurology · doi:10.1001/archneur.56.3.303 · Cited by 8,980
Winblad, B., Palmer, K., Kivipelto, M., Jelic, V., Fratiglioni, L., Wahlund, L. ‐., Nordberg, A., Bäckman, L., Albert, M., Almkvist, O., et al. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01380.x · Cited by 4,946
Clinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814
Harold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., Pahwa, J. S., Moskvina, V., Dowzell, K., Williams, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.440 · Cited by 3,326
Blennow, K., de Leon, M. J., & Zetterberg, H. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69113-7 · Cited by 3,134
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2013) · Focus · doi:10.1176/appi.focus.11.1.96 · Cited by 2,621
Inflammation as a central mechanism in Alzheimer's disease
Kinney, J. W., Bemiller, S. M., Murtishaw, A. S., Leisgang, A. M., Salazar, A. M., & Lamb, B. T. (2018) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.06.014 · Cited by 2,253 · cited 1×
“Due to the dysregulation of GABAergic mechanism in AD, the inhibitory role of GABA on activated microglia is also lost which further contributes to the release of pro-inflammatory cytokines [17].”
Background
Research works printed but not linked: 7
- Grimm M.O.W.; Hartmann T.; Recent understanding of the molecular mechanisms of Alzheimer’s disease. J Addict Res Ther 2012(S5), 004
- Fillit H.M.; We need new biomarkers for Alzheimer’s Disease
- The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines World Health Organization
- Wong C.B.; Kobayashi Y.; Xiao J-Z.; Neuroscience 2018,85-104
- Al-Hameed S.; Benaissa M.; Christensen H.; Simple and robust audio-based detection of biomarkers for Alzheimer’s disease proceeding of the 7th workshop on speech and language processing for Assistive Technologies (SLPAT), San Francisco, USA, 201, pp. 32-36.
- De Brito Sanchez R.; de Barros L.; Rodrigues S.C.M.; Fernandes J.C.L.; Bondioli A.C.V.; de Campos Mundin H.A.; de Sousa V.D.S.; da Silva L.H.B.O.; Artificial Intelligence to Detect Alzheimer’s in Magnetic Resonances, IFMBE Proceedings of the XXVI Brazilian Congress on Biomedical Engineering; Costa-Felix, R.; Machado, J.; Alvarenga, A. (eds), Singapore, Int Psychogeriatr 2019,7(2),59-63
- Farooq A.; Anwar S.M.; Awais M.; Alnowami M.; Proceedings of the IEEE International Smart Cities Conference 2017,1-4
Cited by
Vatansever, S., Schlessinger, A., Wacker, D., Kaniskan, H. Ü., Jin, J., Zhou, M., & Zhang, B. (2021) · Medicinal Research Reviews · doi:10.1002/med.21764 · Cited by 429
“In recent years, AI/ML‐based models have become popular in AD research, mostly utilizing for AD diagnosis and prognosis in dealing with electronic health records and images.(412) On the contrary, AI/ML techniques have not been widely employed in AD drug discovery.”
BackgroundGFAP as a Potential Biomarker for Alzheimer’s Disease: A Systematic Review and Meta-Analysis
Kim, K. Y., Shin, K. Y., & Chang, K.-A. (2023) · Cells · doi:10.3390/cells12091309 · Cited by 309
Wnt signaling pathways in biology and disease: mechanisms and therapeutic advances
Xue, C., Chu, Q., Shi, Q., Zeng, Y., Lu, J., & Li, L. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02142-w · Cited by 281
The role of probiotics and prebiotics in modulating of the gut-brain axis
Ansari, F., Neshat, M., Pourjafar, H., Jafari, S. M., Samakkhah, S. A., & Mirzakhani, E. (2023) · Frontiers in Nutrition · doi:10.3389/fnut.2023.1173660 · Cited by 200
“The basis of the definite diagnosis of AD is through pathological examinations and includes; observation of extracellular plaques with depositions of β-amyloid/Aβ, presence of Aβ in the brain vessels (cerebral amyloid angiopathy (CAA)), and protein forming neurofibrillary tangles associated with intraneural accumulati…”
BackgroundACSL4-Mediated Ferroptosis and Its Potential Role in Central Nervous System Diseases and Injuries
Jia, B., Li, J., Song, Y., & Luo, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241210021 · Cited by 174
“The abnormal folding and aggregation of Aβ in the brain is one of the hallmark pathological changes of Alzheimer’s disease [104].”
Background
Metadata
- Authors
- Khan, S., Barve, K. H., & Kumar, M. S.
- Affiliations
- Narsee Monjee Institute of Management Studies (IN)
- Corresponding author
- Kumar, Maushmi S.
- Venue
- Current Neuropharmacology
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2020-11-09
- Volume
- 18
- Issue
- 11
- Pages
- 1106-1125
- ISSN
- 1570-159X (ISSN-L)
- PMC
- PMC7709159
- OpenAlex
- W3030743313
- Cited by
- 820
- References
- 136
- Citations by year
- 2026: 106 · 2025: 242 · 2024: 234 · 2023: 193 · 2022: 38 · 2021: 4 · 2020: 3
- FWCI
- 7.59
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- cc-by-nc
- Locations
- Current Neuropharmacology (publishedVersion)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- Alzheimer's disease, pathogenesis, early diagnosis, biomarkers, neuroimaging, theranostics, gene therapy, immunotherapy, peptidomimetics, metal chelators, probiotics, quantum dots, artificial intelligence, drug delivery
- MeSH terms
- Alzheimer Disease, Animals, Brain, Humans, Biomarkers, Disease Progression, Early Diagnosis, Neuroimaging
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-29, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-29 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Recent Advancements in Pathogenesis, Diagnostics and Treatment of Alzheimer’s Disease. https://app.cochat.ai/papers/10.2174/1570159x18666200528142429
- The paper
- Khan, S., Barve, K. H., & Kumar, M. S. (2020). Recent Advancements in Pathogenesis, Diagnostics and Treatment of Alzheimer’s Disease. Current Neuropharmacology. https://doi.org/10.2174/1570159x18666200528142429
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.